HK-listed Abbisko hits 7-week peak on AstraZeneca tie-up
BUZZ-HK-listed Abbisko hits 7-week peak on AstraZeneca tie-up ** Shares of clinical-stage biopharmaceutical firm Abbisko Cayman 2256.HK rise 6.5% in the third rising session to HK$11.45, highest level since May 13
** Chinese oncology therapies developer said its unit Abbisko Therapeutics has entered into a strategic collaboration agreement with AstraZeneca AZN.L to jointly advance the clinical development of a novel IO-TKI combination therapy for non-small cell lung cancer
** The investigational new drug application for the combination study was cleared by the National Medical Products Administration, and the Phase II study will be led by Abbisko and both Abbisko and AstraZeneca will share responsibilities for the clinical trial - co
** YTD, stock down 13.9%, Hang Seng Biotech Index .HSBIO down 6.8%
(Reporting by Donny Kwok)
Recent news on Abbisko Medicine
See all newsChina's Abbisko jumps on positive clinical trial results for achondroplasia drug
Brief: Abbisko Cayman Says Unit Completes First Patient Dosing In Phase I Trial Of ABSK211
Brief: Abbisko Cayman Gets IND Clearance From FDA For Oral Small Molecule Pan-Kras Inhibitor ABSK211
HK-listed Abbisko hits 7-week peak on AstraZeneca tie-up
Brief: Abbisko Therapeutics And Astrazeneca Enter A Strategic Collaboration